Biology of mucosally transmitted sexual infection-translating the basic science into novel HIV intervention: A workshop summary

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1389-1396

  Purcell, Damian ^a   Cunningham, Anthony ^b   Turville, Stuart ^c   Tachedjian, Gilda ^d,e   Landay, Alan ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BURNET INSTITUTE   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA DEFENSIN 2; CD14 ANTIGEN; CD209 ANTIGEN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON; INTERFERON EPSILON; INTERLEUKIN 8; LACTIC ACID; MARAVIROC; MEDROXYPROGESTERONE ACETATE; MICROBICIDE; NONOXINOL 9; RALTEGRAVIR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SHORT CHAIN FATTY ACID; TENOFOVIR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AUSTRALIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LANGERHANS CELL; MICROFLORA; MUCOSAL DISEASE; NONHUMAN; PRIORITY JOURNAL; SEMINAL PLASMA; SEXUALLY TRANSMITTED DISEASE; VAGINAL LAVAGE; VIRION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS LOAD; VIRUS TRANSMISSION;

ADAPTIVE IMMUNITY; AIDS VACCINES; ANIMALS; ANTI-INFECTIVE AGENTS; AUSTRALIA; FEMALE; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MALE; MODELS, ANIMAL; MUCOUS MEMBRANE; SEXUAL BEHAVIOR;

EID: 84868553141     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0276     Document Type: Conference Paper

References (38)

1. Dinh MH, Okocha EA, Koons A, Veazey RS, and Hope TJ: Expression of structural proteins in human female and male genital epithelia and implications for sexually transmitted infections. Biol Reprod 2012;86(2):1-6.
2. Aggarwal A, Lemma TL, Shih TP, et al.: Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected dendritic cells. PLoS Pathogens 2012;8:e1002762.
3. Hladik F and Hope TJ: HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009;6(1):20-28.
4. Wira CR and Fahey JV: A new strategy to understand how HIV infects women: Identification of a window of vulnerability during the menstrual cycle. AIDS 2008;22(15):1909-1917.
5. Cunningham AL, Abendroth A, Jones C, Nasr N, and Turville S: Viruses and Langerhans cells. Immunol Cell Biol 2010;88:416-423.
6. Cunningham AL, Carbone F, and Geijtenbeek TB: Langerhans cells and viral immunity. Eur J Immunol 2008;38:2377-2385.
7. Pudney J, Quayle AJ, and Anderson DJ: Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005;73:1253-1263.
8. Pudney J and Anderson D: Innate and acquired immunity in the human penile urethra. J Reprod Immunol 2011;88:219-227.
9. Mirmonsef P, Zariffard MR, Gilbert D, Makinde H, Landay AL, and Spear GT: Short-chain fatty acids induce pro-inflammatory cytokine production alone and in combination with toll-like receptor ligands. Am J Reprod Immunol 2012; 67(5):391-400.
10. Atashili J, Poole C, Ndumbe PM, Adimora AA, and Smith JS: Bacterial vaginosis and HIV acquisition: A meta-analysis of published studies. AIDS 2008;22:1493-1501.
11. Cohen CR, Lingappa JR, Baeten JM, et al.: Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: A prospective cohort analysis among African couples. PLoS Med 2012;9:e1001251.
12. Boskey ER, Cone RA, Whaley KJ, and Moench TR: Origins of vaginal acidity: High D/L lactate ratio is consistent with bacteria being the primary source Hum Reprod 2001;16:1809-1813.
13. O'Hanlon DE, Moench TR, and Cone RA: In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis 2011;11:1-8.
14. Lai SK, Hida K, Shukair S, et al.: Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009;83:11196-11200.
15. Hertzog PJ: Overview. Type I interferons as primers, activators and inhibitors of innate and adaptive immune responses. Immunol Cell Biol 2012;90:471-473.
16. Berry CM, Hertzog PJ, and Mangan NE: Interferons as bio-markers and effectors: Lessons learned from animal models. Biomark Med 2012;6:159-176.
17. Xi Y, Day SL, Jackson RJ, and Ranasinghe C: Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucosal Immunol 2012 [Epub ahead of print]; DOI:10.1038/mi.2012.35.
18. Denton PW and Garcia JV: Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 2012;20:268-274.
19. Denton PW, Othieno F, Martinez-Torres F, et al.: One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 2011;85:7582-7593.
20. Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, and Mayer KH: Targeting Trojan Horse leukocytes for HIV prevention. AIDS 2010;24:163-187.
21. Anderson DJ: Finally, a macaque model for cell-associated SIV/HIV vaginal transmission. J Infect Dis 2010;202:333-336.
22. Doncel GF, Joseph T, and Thurman AR: Role of semen in HIV-1 transmission: Inhibitor or facilitator? Am J Reprod Immunol 2011;65:292-301.
23. Veselinovic M, Preston NC, Mulder LR, and Akkina R: Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 2012;432(2):505-510.
24. Veazey RS, Shattock RJ, Klasse PJ, and Moore JP: Animal models for microbicide studies. Curr HIV Res 2012;10:79-87.
25. Otten RA, Adams DR, Kim CN, et al.: Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: Strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis 2005;191:164-173.
26. Vishwanathan SA, Guenthner PC, Lin CY, et al.: High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011;57:261-264.
27. Veazey RS, Klasse PJ, Schader SM, et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438:99-102.
28. Lederman MM, Veazey RS, Offord R, et al.: Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306:485-487.
29. Veazey RS, Shattock RJ, Pope M, et al.: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003;9:343-346.
30. Sweeney YT, Angeles RO, Cummings PK, Smith AD, and Patton DL: Pigtailed macaque model refinement: Topical microbicide safety in the presence of coitus. J Med Primatol 2011;40:327-334.
31. Rohan LC, Moncla BJ, Kunjara N Ayudhya RP, et al.: In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010;5(2):e9310.
32. CN54, clade C, trimeric envelope vaccine candidate delivered vaginally. PLoS One 2011;6:e25165.
33. Cranage MP, Fraser CA, Cope A, et al.: Antibody responses after intravaginal immunization with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccines 2011;29:1421-1430.
34. Cranage M, Sharpe S, and Herrera C: Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008;5:e157.
35. Cheng-Mayer C, Huang Y, Gettie A, et al.: Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide. AIDS 2011;25:1833-1841.
36. Barouch DH, Klasse PJ, Dufour J, Veazey RS, and Moore JP: Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci USA 2012;109:8694-8698.
37. Kramski M, Center RJ, Wheatley AK, et al.: Hyperimmune bovine colostrums as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. Antimicrob Agents Chemother 2012;56(8):4310-4319.
38. Lichtfuss M, Navis G, Kramski M, et al.: Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrums IgG. Eur J Immunol 2012. [Epub ahead of print]; DOI:10.1002/eji.201242469.